Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

Abstract Background Pain is one of the most important domains affecting health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Secukinumab has demonstrated rapid and sustained improvements in signs and symptoms, including HRQoL, among patients with active PsA. This analys...

Full description

Bibliographic Details
Main Authors: Iain B. McInnes, Philip J. Mease, Georg Schett, Bruce Kirkham, Vibeke Strand, Nicole Williams, Todd Fox, Luminita Pricop, Steffen M. Jugl, Kunal K. Gandhi, on behalf of the FUTURE 2 Study Group
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Arthritis Research & Therapy
Subjects:
Pain relief
Psoriatic arthritis
Secukinumab
Online Access:http://link.springer.com/article/10.1186/s13075-018-1610-3

Internet

http://link.springer.com/article/10.1186/s13075-018-1610-3

Similar Items